Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181818 · ClinicalTrials.gov registry record · Phase 4
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
A Phase 4 study of Cardiovascular Disease and Smoking, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
- 1
- Study location
NCT00181818 is a Phase 4 study of Cardiovascular Disease and Smoking that has completed, run by Massachusetts General Hospital. The registered enrollment target is 248 participants, below the 2,712-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00181818, a Phase 4 study of Cardiovascular Disease and Smoking, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test the efficacy and safety of bupropion SR for smokers hospitalized with acute cardiovascular disease.
Conditions Studied
Interventions
- DRUG bupropion SR (sustained-release)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 1999-10 |
| Est. Completion | 2003-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181818
The ClinicalTrials.gov registry entry for NCT00181818 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,712-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (91% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which bupropion SR (sustained-release) is the first listed.
NCT00181818 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00181818 about?
NCT00181818 is a clinical study titled "Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease". The purpose of the study is to test the efficacy and safety of bupropion SR for smokers hospitalized with acute cardiovascular disease.
What is the current status of trial NCT00181818?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 1999-10. Estimated completion is 2003-12.
What conditions does trial NCT00181818 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Smoking, Myocardial Infarction, Unstable Angina.
What interventions are being tested in trial NCT00181818?
The interventions under investigation include: bupropion SR (sustained-release) (DRUG).
Who is sponsoring clinical trial NCT00181818?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00181818 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beta-Blocker Influences on Inflammatory and Neural Responses to Stress
RECRUITING · Phase 4
-
Randomized Trial of SGLT2i in Heart Transplant Recipients
RECRUITING · Phase 4
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
MIcrovascular dysfuNction In Moderate-severe Psoriasis
COMPLETED · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.